GlassScriptPhysician profile
Peter J Duncanson
NPI 1861461048
$1,016.24
in general payments reported to CMS, 2019-2025
27 companies · $102 in 2025
The $102 reported for 2025 was less than what a typical Surgical provider received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $258 · 2022: $266 · 2023: $230 · 2024: $159 · 2025: $102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $492.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $491.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $137.75 | 2023 | Olumiant, Trulicity, Mounjaro |
| Novo Nordisk INC | $116.14 | 2022 | |
| Davol INC. | $99.43 | 2021-2023 | Progel Applicator Spray Tips |
| Pacira Therapeutics, INC. | $86.98 | 2021 | |
| Si-Bone, INC. | $72.17 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $50.17 | 2022 | |
| Sanofi Pasteur INC. | $36.75 | 2022 | |
| Saluda Medical Americas, INC. | $35.50 | 2024 | Evoke |
| Vertex Pharmaceuticals Incorporated | $33.70 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.33 | 2022 | |
| Baxter Healthcare | $30.56 | 2025 | Tisseel |
| Nevro Corp. | $28.98 | 2024 | Senza |
| Spr Therapeutics, INC | $25.67 | 2024 | Sprint Pns System |
| Novartis Pharmaceuticals Corporation | $23.32 | 2023 | |
| Stryker Corporation | $19.99 | 2024 | Optablate |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $19.48 | 2024 | Qutenza |
| Bioventus LLC | $19.17 | 2025 | Durolane |
| Ferring Pharmaceuticals INC. | $18.88 | 2025 | Euflexxa |
| Amgen INC. | $18.56 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $18.52 | 2021 | |
| Djo, LLC | $15.51 | 2023 | Aircast, Cmf, Procare |
| Collegium Pharmaceutical, INC. | $14.88 | 2024 | Belbuca |
| Boston Scientific Corporation | $14.81 | 2024 | Watchman Access System |
| Dexcom, INC. | $14.49 | 2023 | Dexcom G6 Transmitter |
| Pfizer INC. | $14.00 | 2023 | |
| Merck Sharp & Dohme LLC | $13.54 | 2022 | |
| Orthofix Medical, INC. | $5.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Duncanson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.